Home / Europe / Bulgaria / Life Sciences & Healthcare

Life Sciences & Healthcare

We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.  Our life sciences & healthcare teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 480 international specialist lawyers across CMS and the support of the Life Sciences & Healthcare Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences & healthcare sector. We regularly advise our clients on their day-to-day operational needs, providing support with advertisement and promotion of medicines, public sector procurement, pricing and reimbursement, patent enforcement and commercial and clinical trial agreements, as well as regulatory advice.


Feed

02/08/2022
Leg­al is­sues in the meta­verse / Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial...
Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial In­tel­li­gence Reg­u­la­tion, the meta­verse as a work­place In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world. The emer­gence...
27/07/2022
Leg­al is­sues in the meta­verse / Part 3 - Data pro­tec­tion chal­lenges, the...
Part 3 - Data pro­tec­tion chal­lenges, the im­port­ance of cy­ber­se­cur­ity, ad­vert­ising reg­u­la­tion in the meta­verse In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world...
19/07/2022
Leg­al is­sues in the meta­verse / Part 2 - Trade­marks and copy­right, NFTs...
Part 2 - Trade­marks and copy­right, NFTs and civil law prin­ciples in the meta­verse In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world. In the meta­verse, trade in vir­tu­al...
15/07/2022
EU­'s Gen­er­al Court con­firms Com­mis­sion's new mer­ger re­fer­ral policy in...
Un­der Art­icle 22 of the EU Mer­ger Reg­u­la­tion (EU­MR), na­tion­al com­pet­i­tion au­thor­it­ies have the pos­sib­il­ity to re­quest re­fer­ral to the Com­mis­sion of any mer­ger, which does not meet the thresholds of the...
07/06/2022
Trade secret laws and reg­u­la­tions in Bul­garia
Gen­er­al 1. Has the Dir­ect­ive (EU) 2016/943 of the European Par­lia­ment and of the Coun­cil of 8 June 2016 on the pro­tec­tion of un­dis­closed know-how and busi­ness in­form­a­tion (trade secrets) against their...
Comparable
01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
26/05/2022
Schrems II: Re­ac­tions to the judge­ment and the su­per­vis­ory au­thor­it­ies'...
“Schrems II”: Opin­ions of the su­per­vis­ory au­thor­it­ies on Schrems II and re­com­mend­a­tions on the im­ple­ment­a­tion of the judge­ment in in­ter­na­tion­al data trans­fers On 16 Ju­ly 2020, the Court of Justice...
19/05/2022
Can­nabis law and le­gis­la­tion in Bul­garia
Med­ic­al use Bul­gari­an le­gis­la­tion does not al­low the use of can­nabis for med­ic­al pur­poses.The use, cul­tiv­a­tion, im­port, ex­port and con­trol of can­nabis is gen­er­ally reg­u­lated by the Bul­gari­an Nar­cot­ic...
21/04/2022
Bul­garia to grant Ukrain­i­ans flee­ing war with free ac­cess to health­care
Fol­low­ing the re­cent mil­it­ary crisis in Ukraine, a num­ber of Ukrain­i­ans ar­rived in Bul­garia to seek tem­por­ary pro­tec­tion or asylum. On 14 April 2022, the Bul­gari­an Na­tion­al As­sembled ad­op­ted a draft...
08/04/2022
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence – a step...
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence (the “CSDD Pro­pos­al”), pub­lished on 23 Feb­ru­ary 2022, aims to im­pose ob­lig­a­tions on com­pan­ies, their sub­si­di­ar­ies and their value chains...
05/04/2022
Re­cent up­dates to the EPO Guidelines for Ex­am­in­a­tion rel­ev­ant to in­ven­tions...
An amended ver­sion of the EPO Guidelines for Ex­am­in­a­tion entered in­to force on 1 March 2022, su­per­sed­ing the edi­tion of March 2021. Here we re­view the up­dates rel­ev­ant to in­ven­tions in the field of bi­o­tech­no­logy...
24/03/2022
Bul­garia in­tro­duces pro­ced­ure for au­thor­isa­tion of clin­ic­al tri­als per...
EU Reg­u­la­tion No. 536/2014 of the European Par­lia­ment and of the Coun­cil of 16 April 2014 on clin­ic­al tri­als on medi­cin­al products for hu­man use and re­peal­ing Dir­ect­ive 2001/20/EC (Clin­ic­al Tri­als Reg­u­la­tion...